Evotec AG entered its second scientific discovery collaboration with Harvard University inside a year. The company is teaming up with Harvard scientists Andy McMahon and Ben Humphreys on an initiative called CureNephron to identify novel targets – and drugs acting on them – that have disease-modifying potential in a range of kidney indications.